Medidata Solutions (MDSO) Upgraded by BidaskClub to “Hold”
BidaskClub upgraded shares of Medidata Solutions (NASDAQ:MDSO) from a sell rating to a hold rating in a report released on Tuesday.
Several other analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of Medidata Solutions from a hold rating to a sell rating in a report on Wednesday, December 27th. TheStreet downgraded shares of Medidata Solutions from a b rating to a c+ rating in a report on Thursday, December 14th. Deutsche Bank assumed coverage on shares of Medidata Solutions in a report on Friday, December 8th. They issued a buy rating and a $78.00 target price on the stock. Wells Fargo & Co raised shares of Medidata Solutions from a market perform rating to an outperform rating and set a $80.00 target price on the stock in a report on Friday, December 1st. Finally, Dougherty & Co raised shares of Medidata Solutions from a neutral rating to a buy rating and set a $75.00 target price on the stock in a report on Monday, November 13th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the stock. Medidata Solutions currently has a consensus rating of Buy and an average target price of $84.54.
Shares of Medidata Solutions (MDSO) traded up $0.30 during trading on Tuesday, reaching $67.20. 620,700 shares of the company’s stock traded hands, compared to its average volume of 450,800. Medidata Solutions has a 52 week low of $47.77 and a 52 week high of $85.92. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.29 and a quick ratio of 3.37. The stock has a market cap of $3,911.04, a P/E ratio of 96.00, a P/E/G ratio of 3.47 and a beta of 1.69.
In related news, CFO Rouven Bergmann sold 2,000 shares of the firm’s stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $65.40, for a total value of $130,800.00. Following the completion of the sale, the chief financial officer now owns 91,775 shares in the company, valued at $6,002,085. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael I. Otner sold 10,000 shares of the firm’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $70.88, for a total transaction of $708,800.00. Following the completion of the sale, the executive vice president now owns 80,674 shares of the company’s stock, valued at approximately $5,718,173.12. The disclosure for this sale can be found here. Insiders sold 239,010 shares of company stock valued at $16,437,036 in the last quarter. Company insiders own 5.80% of the company’s stock.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Fortaleza Asset Management Inc. acquired a new stake in shares of Medidata Solutions in the third quarter valued at about $155,000. Polen Capital Management LLC acquired a new stake in shares of Medidata Solutions in the third quarter valued at about $205,000. Cubist Systematic Strategies LLC acquired a new position in Medidata Solutions during the second quarter worth about $227,000. ETF Managers Group LLC acquired a new position in Medidata Solutions during the second quarter worth about $233,000. Finally, Hanseatic Management Services Inc. raised its position in Medidata Solutions by 14,915.0% during the third quarter. Hanseatic Management Services Inc. now owns 3,003 shares of the company’s stock worth $234,000 after acquiring an additional 2,983 shares during the last quarter.
Medidata Solutions Company Profile
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Stock Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related stocks with our FREE daily email newsletter.